IE46866B1 - Veterinary compositions - Google Patents

Veterinary compositions

Info

Publication number
IE46866B1
IE46866B1 IE730/78A IE73078A IE46866B1 IE 46866 B1 IE46866 B1 IE 46866B1 IE 730/78 A IE730/78 A IE 730/78A IE 73078 A IE73078 A IE 73078A IE 46866 B1 IE46866 B1 IE 46866B1
Authority
IE
Ireland
Prior art keywords
sulphaquinoxaline
veterinary composition
trimethoprim
present
salt
Prior art date
Application number
IE730/78A
Other versions
IE780730L (en
Inventor
Howaito Jofurei
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IE780730L publication Critical patent/IE780730L/en
Publication of IE46866B1 publication Critical patent/IE46866B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/137Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

The invention relates to preparations suitable for use in veterinary medicine, in particular to preparations which are suitable for the treatment of diseases in poulty caused by bacteria and protozoa. The preparations are distinguished in that they contain an effective amount of trimethoprim in combination with an active amount of sulfaquinoxaline in a weight ratio of trimethoprim to sulfaquinoxaline of 1 : 1 to 1 : 4.

Description

The present invention relates to compositions useful in veterinary medicine and more particularly in the treatment of bacterial and protozoal diseases in poultry.
Coccidiosis is a common disease in poultry caused by species of protozoal parasites of the genus Eimeria. The infection commonly occurs in poultry between the ages of two and fourteen weeks and can cause widespread losses if left unattended. The prevention and treatment of coccidiosis in poultry husbandry is therefore of extreme economic importance.
One medicament often used in therapeutic preparations for treating coccidiosis is sulphaquinoxaline [N(2-quinoxalyl)sulphanilamideJ, which is described in the textbook of Organic Medicine and Pharmaceutical Chemistry, 4th Edition, J.B. lippincott Co., Philadelphia, but this is unfortunately toxic in large doses. It has been commonly found that by combining sulphonamides with a particular group of compounds the efficacy of the sulphonamide as an antibacterial agent is maintained whilst the dose required is reduced. In recent years several preparations for treating coccidiosis have contained sulphaquinoxaline in combination with diaveridine £2,4-diamino-5-(3,4-dimethoxybenzyl) -3pyrimidinej, a sulphonamide potentiator. Patent Specifications Nos. 28055 and 29519 describe such preparations.
Trimethoprim [2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine} is on the other hand an antibacterial agent which has been commonly used in admixture with certain sulphonamides such as sulphathiazole, sulphamethoxazole, sulphadiazine, sulphadimidine and sulphadoxin in man and mammals. However, it has not previously been suggested that trimethoprim may be combined with sulphaquinoxaline for the treatment of coccidiosia in poultry.
It has now been found that preparations containing trimethoprim and sulphaquinoxaline provide an effective and improved treatment of coccidiosia including coccidiosis caused by sulphaquinoxaline resistant strains of protozoa of the genus Eimeria. This admixture is also unexpectedly efficaceous against bacterial infections including those caused by certain sulphonamide resistant strains of Escherichia coli and in the treatment of malaria in poultry. This is particularly surprising as it has been suggested (lewis, Anderson and lacey, J.Clin. Path,, 1974, 27, 87-91)that potentiation between sulphonamides and trimethoprim does not occur in vitro when the infection is sulphonamide resistant.
Accordingly the present invention provides a veterinary composition which comprises trimethoprim or a salt thereof in admixture with sulphaquinoxaline or a salt thereof, the weight ratio of trimethoprim present 4-6S6 6 -4to sulphaquinoxaline present being from 1:1 to 1:4.
Conveniently trimethoprim may be present as a free base and sulphaquinoxaline as a salt with a veterinarily acceptable base.
It is also possible to use trimethoprim as an acid addition salt, e.g. as a salt formed with a veterinarily acceptable acid, together with the free sulphaquinoxaline, or have both active ingredients present in their free unsalted forms.
Preferably the weight ratio of trimethoprim to sulphaquinoxaline is about 1:3.
In a preferred aspect the present invention provides a veterinary composition which comprises trimethoprim in admixture with a veterinarily acceptable salt of sulphaquinoxaline, the weight ratio of trimethoprim present to sulphaquinoxaline present as hereinbefore defined.
The veterinary compositions of the present invention are normally in either powder or liquid concentrate form. In the powders of the present invention it is preferred to use an alkali metal salt of sulphaquinoxaline, such as its sodium salt. In accordance with standard veterinary formulation practice, conventional water soluble excipients, such as lactose or sucrose, may be incorporated in the powders to improve their physical properties. Thus particularly suitable powders of this invention comprise 50 to 100$ w/w, and preferably 60-80$ w/w, of a mixture of trimethoprim with sulphaquinoxaline, preferably as an alkali metal salt, and 0-50$ w/w, and -5preferably 20-40# w/w, of conventional veterinary excipients, the ratio of trimethoprim present to sulphaquinoxaline present being as hereinbefore defined.
These powders may either be added to animal feedstuffs, for example by way of an intermediate premix, or diluted in animal drinking water. It has been found that dilution of a powder of this invention in water to give about 135 ppm of trimethoprim and sulphaquinoxaline as active ingredients is particularly efficacious for poultry. Thus 20g of powder containing 70# w/w of a mixture of trimethoprim with sodium sulphaquinoxaline may be added to 100 litres of drinking water to provide an effective treatment for poultry. liquid concentrates of this invention suitably contain trimethoprim and a water soluble veterinarily acceptable salt of sulphaquinoxaline formed from mixing a solution of sulphaquinoxaline with a water soluble base and in particular an organic base such as ethanolamine or diethanolamine in a veterinarily acceptable water miscible solvent. Suitable solvents include polyethylene glycol, propylene glycol, glycerol, glycerol formal or such a solvent mixed with up to 30# v/v of ethanol. It has been found that polyethylene glycol is a particularly convenient solvent for use in the liquid concentrates of this invention. Suitably a salt of sulphaquinoxaline is formed in situ by having an organic base present with sulphaquinoxaline in the liquid concentrate.
Thus in a further preferred aspect the present -6invention provides a liquid concentrate which comprises 10-505^ w/v and preferably 245" w/v, of a mixture of trimethoprim with a salt of sulphaquinoxaline formed from a veterinarily acceptable water soluble organic base, in a solvent selected from glycol, propylene glycol, glycerol and glycerol formal, the weight ratio of trimethoprim to sulphaquinoxaline being as hereinbefore defined.
The liquid concentrates of this invention will be 10 administered to the drinking water of animals, particularly poultry. They are particularly suitable for automatic addition to the drinking water of poultry by using water proportioned. The veterinary compositions of the present invention are particularly suitable for the treatment of coccidiosis in chickens.
In another aspect the present invention provides a method of treatment of bacterial diseases in poultry which comprises the oral administration of 1 to 100 mg/kg of a veterinary composition of the present invention as hereinbefore described.
Suitably 5 to 70 mg/kg, and preferably 20 to 40 mg/ kg of a composition of the present invention is orally administered daily by providing the composition in the feedstuff or drinking water of poultry in the treatment of bacterial diseases.
In a further aspect the present invention provides a method of treatment of protozoal diseases, in particular coccidiosis and malaria, and bacterial infections in -7birds such as poultry which comprises the oral daily administration of the above mentioned dosages of a veterinary composition as hereinbefore described.
The present invention also provides a method of treatment of malaria in poultry which comprises the oral daily administration of the abovementioned dosages of a veterinary composition as hereinbefore described.
The following examples demonstrate the veterinary efficacy of the formulations and their preparation. The percentage, weight to volume concentrations referred to herein are in g/100 ml.
Antibacterial and antiprotozoal activity of trimethoprim/aulphaquinoxaline formulations Chicks which had been infected by sulphonamide resistant E. coli strain 18EC were treated with a trimethoprim/sulphaquinoxaline formulation at different dose levels, (E. coll strain 18EC induces a syndrome clearly resembling Coli-septicaemia which is a serious commonly occurring disease of broilers; see Piercy and West, J. Comp. Path., (1976) 86 205). Similarly infected chicks were also treated with a trimethoprim formulation and the two commercially used formulations, sulphachloropyridazine and oxytetracycline, for comparison purposes.
The chicks were infected and weighed when 18 days old. Seven days after infection the birds were killed, weighed again and a post-mortem examination carried out.
All the chicks, apart from the uninfected and infected untreated controls were offered medicated drinking water ad lib from 24 hours before infection with no further access to unmedicated water until the treatment ended. The drum levels and treatment periods are shown in Table 1 which gives the observations recorded at post-mortem examination. The extent of lesions observed at post-mortem examination was recorded on a scale of 0 to 4 on the following basis: Score No. lesions Inflammatory reaction in injected air sac Inflammation of both air sacs Severe bilaterial airsacculitis plus pericarditis All above symptoms plus fibrinous peritonitis, or death -9TABLE 1 >5 ρ Ρ Ρ ed ρ Ρ ο Ό Λ ΦΡ Ρ d ο bo ω <Η Ρ £ Ρ β Η Ρ Ο k Ο ο Ρ^ V-* >» cd β ό ρ ed r* bC β ο ρ Ρ Ρ Α Ρ ττ 03 eti Ρ κ\ φ to ο ϋ WCM β ο Ρ (0 φ ΗΐΗ a o o o o o o CM CM CM CM CM CM CM CM CM CM CM \ X CM P P P LA o fA CM O φ ρ Ρ Η cd κ ο ΰ •Η Ρ Ο* cd Λ Ρι Η Ρ Cm CO •Nf H > tA o co Py • ♦ • • • • o O CM CM cn CM C- o 00 o Λ CM co 00 c— fA P P Φ ε Ρ β Ρ LA O LA σ LA o o o LA ·· • • • • • • • • • P • o tA e* o LO P P t> to LA cn co 00 A- fr- & P CM ed Φ P P P P P CM P cd Ο CM LO LD Ρ ΙΑ Ρ CM Ρ cm ω ρ ο β Ρ Ρ Ο ϋ β Ρί Ο Ρ Ρ Ρ Τ3 β φ Ρ Ρ Ο Ρ 03 Ρ Ρ ’τ&'ϋ 0) fi o CQ <** •P o o O 03 co « 03 03 0) ·Ρ P cd P LA >j >> Bt +» 'd cd A- ed co cd cd a) O’ oo T3 »ρ τ3 «3 h ω Φ w ω fi +>^> Φ φ φ Φ φ Φ CM >5 Ό Ρ Φ 0}Ρ Ρ cd Ό cd ΛΡ Φ φ • ΡΡ Ρ β Ρ Ρ Ρ 0 ρ ο s Ώ φ β β «Η 3 Ρ Ρ β β φ ο Ρ ΟΡΟ Ρ φ ϋ co h Ρ> Ρ Φ Ρ ο-σ h ω Φ ΦΡ Ρ Ρ Φ β ϋ ω R Ρ ο Ε ο <Η ® Η φ Ε ϊ >j Ρ •Η Λ Φ βχίΡ ► ? ® Ό h ω « «η 01 Μ Ο Ρ β Ρ rgs? ρ Κ\ β tA^ Ρ S'Ε4 fA > fA > ΪΑΡ CM Ρ ιη·Η Ρ Ρ Ρ Ρυ «Η Ρ ft Ο «Η Ρ β 03 fA ft— Ο'»·*' ΙΑ''-' β β β S 5S SK fA Μθ I* * Ρ GH &4 ε-ι Ρ CM 1 1 Ρ CM ΟΛ φ Ρ. ρ ο & to σι ο rah ft ft ft fi fi fi 3 += ο ο ο K h h h *H cs ΰ ts a >4-6866 TABLE 1 β •Η τ5 Φ φ Η • -Ρ Ρ J4 2 Φ ω Η Ρ -Ρ ·Η Ο α} τ3 Φ £ •γρ >> β β Η •Η «Ο •rl Φ β -Τ) -Ρ •Η ω ή Ο -Ρ 2 b 3 ω 0 Η φ •η α> fd Ί3 β Ρ •Η Φ Μ Ε4 Η Φ fi ϋ Fd β Ρ >9 Ο Ή ft •Η β ο Ρ Φ R β Ο Η βΗ Ο Ο Λ •Η Ο Φ © Φ Φ β Λ β /—s φ ft •rl τί ftH Η φ to β Ο β 3 ω >9 β © Ο •Η <Ρ Φ Ή θ ο R · ίί •Η •Ρ fd Ο Ρ -Ρ φ φ Ο ftH -Ρ -Ρ Ο Φ >5>Φ 34 Μ Μ £ -Ρ ο Φ 0 β 0 β Η Η Ή *rl J3 Ρ Ό’ \*ό -Ρ ο U0 Φ ω 0-Ρ β 00 Φ ΟΗ ,β ιη·Η β-Ρ Ό Φ Φ ρβ r*s Λ-Ρ rP Η •Ρ ·Η ΡρΟ •Η £ •Η Φ & £-Ρ π4 •rl nS Φ *β β Φ-Ρ Φ Μ •ρ cd Ρ φ φ Π)^ φ ρ 0) β Ρ-Ρ β ω -Ρ -Ρ Ν φ •Η . φ β Φ «Η β £ ΦΗ £ * β ιη\ο Ε> Ο « Η ί Ρί* β β ω1 β β ο Ο -Ρ ΟΗ R Ρ Φ R ο Ο d? © 4-6866 -11Groups of five, one week old Ranger cockerels were each infected orally with a mixture of 50,000 sporulated oocysts of the Ongar strain of E. acervulina and 50,000 oocysts of the Weybridge strain of E. maxima and 50,000 oocysts of the Weybridge strain of E. brunetti. This produced 72# mortality in unmedicated chicks. The chicks were treated with a 3:1 Sulphaquinoxaline/trimethoprim formulation in drinking water (final concentration 132 ppm). Rive day treatments were begun on the day of infection and one and two days afterwards. Infected untreated and uninfected untreated groups were included as controls the latter receiving a water innoculation. Table 2 shows the weight gains of the chickB after the periods from 0-4, 4-7, 7-14 and 0-14 days (day 0 = day of infection). The treatment controlled both mortality and haemorrhage/diarrhoea completely. -12TABIE 2 Percentage weight gain of chicks during and after treatment with a 3si Sulphaquinoxaline/ trimethoprim formulation Wt. gain Vit. gains/chick (g)* 0-14 as Treatment . days # control 0-4 4-7 7-14 0-14 Unmedicated uninfected 35.5a 33.1a 97.3a 165.9s 100.0 Unmedicated infected 17-6b 5.2b 75.7b 98.5b 59.4 TMP/SQ days 0 to 5 32. la 31.0a 85.6b 148.7° 89.6 TMP/SQ days 1 to 6 33.2a 29.9s 84.0b 147.1° 88.7 TMP/SQ days 2 to 7 32.4a 28.5a 87.6s 148.5° 89.5 *In each column, figures sharing the same superscripts are not statistically different at the 5# level.
Groups of 5, one week old Ranger cockerels were infected orally with 50,000 sporulated oocysts of the Weybridge strain of Ei. tenella. This produced 75.5 per cent mortality in unmedicated chicks. The chicks were treated with 4:1 Sulphaquinoxaline diaveridine solution (final concentration 96 ppm) and with a 5si Sulphaquinoxaline/trimethoprim solution (final concentration 155 ppm). Treatments were begun on the day of infection and lasted for 5 and 4 days. The details of mortality control are shown in Table 3. The Sulphaquinoxaline/diaveridine solution gave 95# protection -13against mortality after a three day treatment and 100% protection for four day treatment whilst Sulphaquinoxaline/trimethoprim formulations gave 100% protection for both the three and four day treatments.
TABLE 3 Percentage protection against mortality due to Ei tenella by treatment with a aulphaquinoxaline/diaveridine formulation and Sulphaquinoxaline/trimethoprim formulation (the percentages are baaed on the results obtained from 50 chicks).
Treatment Regime (days)· 0-3 0-4 Sulphaquinoxaline/ diaveridine : 4:1 94.9 100.0 Sulphaquinoxaline/ trimethoprim : 3:1 100.0 100.0 Groups of five, one-week old Ranger cockerels were each infected orally with 250,000 sporulated oocysts of the sulphaquinoxaline resistant Dessord Mill Strain of E. aoervulina. The chicks were treated with a 3:1 sulphaquinoxaline/trimethoprim formulation in drinking water (final concentration 132 ppm). Five day treatments were begun on the day of infection and one and two days afterwards. Infected untreated and uninfected untreated groups were included as controls, the latter receiving doses water by gavage as sham-infections. Table 3 shows the weight gains of the chicks after -14periods of 0-4, 4-7, 7-14 and 0-14 days (day 0 is the day of infection). Over the whole 14 days, all treated groups achieved weight gains significantly better than those of infected controls and about 97% over-all of the uninfected controls. The results are shown in Table 4.
TABLE 4 Weight gains per chick during and after treatment with TMP/SQ (55/99 p.p.m.) in the drinking water following infection with sulphaquinoxaline-resistant E. acervulina.
Y/t 0-4 . gains/chiok (g)* during days :4-7 7-14 0-14 Y/t. gain 0-14 as / control Unmedicated uninfected 24.8a 27.6a 83.6a 136.la 100.0 Unmedicated infected 20.3b 13.7b 75.2b IO9.2b 80.2 TMP/SQ Bays 0-5 28.4° 28.5° 82.3ab 139.2a 102.3 TMP/SQ Bays 1-6 28.7° 22.7d 87.0a 138.4a 101.7 TMP/SQ Bays 2-7 23.2a 25.0ad 78. lb 126.3° 92.8 *In each column, figures showing the same superscripts are not statistically significantly different at the 5/ level.
EXAMPLES Example 1 A 24/ solution of a 3:1 sulphaquinoxaline/trimethoprim formulation was prepared having the following composition: -15Trimethoprim Sulphaquinoxaline Monoethanolamine g Polyethylene Glycol 200 to 100 ml The trimethoprim was dissolved in 70 ml of the Polyethylene Glycol 200 heated to 70-80°C. The Monoethanolamine and sulphaquinoxaline were added and the mixture stirred until the contents had dissolved. The solution was cooled to room temperature and made up to volume with Polyethylene Glycol 200. The resulting solution was throughly mixed to ensure is homogeneity.
Example 2 A soluble powder containing a 3:1 formulation of sulphaquinoxaline/trimethoprim was prepared having the following composition: Sulphaquinoxaline Sodium 10.73 g Trimethoprim 3.3 g Sodium Lauryl Sulphate 0.1 g Lactose 5.87 g The Lactose, trimethoprim and sulphaquinoxaline sodium were throughly mixed together in a mixer. The sodium lauryl sulphate was dissolved in a small quantity of water and this solution was used to granulate the powders. The resulting granules were sieved and dried and the dried granules again sieved. The sieved dried granules were thoroughly mixed so that they were in a form suitable for administration to animal feedstuffs or animal drinking water.

Claims (19)

1. 1. WHAT WE CLAIM IS:1. A veterinary composition which comprises trimethoprim or an acid addition salt thereof in admixture with sulphaquinoxaline or a salt thereof, the weight ratio of trimethoprim present to sulphaquinoxaline present being from 1:1 to 1:4.
2. A veterinary composition as claimed in claim 1 wherein the weight ratio of trimethoprim present to sulphaquinoxaline present is about 1:3.
3. A veterinary composition as claimed in either claim 1 or claim 2 wherein the trimethoprim is present as the free base.
4. A veterinary composition as claimed in any one of claims 1 to 3 wherein the sulphaquinoxaline is present as a salt with a veterinarily acceptable base.
5. A veterinary composition as claimed in any one of claims 1 to 4 in the form of a powder.
6. A veterinary composition as claimed in claim 5 wherein the sulphaquinoxaline is present in the form of an alkali metal salt.
7. A veterinary composition as claimed in claim 6 wherein the alkali metal salt of sulphaquinoxaline is the sodium salt.
8. A veterinary composition as claimed in any one of claims 5 to 7 wherein the powder comprises 50 to 100# w/w of a mixture of trimethoprim and sulphaquinoxaline.
9. A veterinary composition as claimed in any one -18of claims 5 to 8 wherein the powder comprises 60 to 80% w/w of a mixture of trimethoprim and sulphaquinoxaline.
10. A veterinary composition as claimed in any one of claims 1 to 4 in the form of a liquid concentrate.
11. A veterinary composition as claimed in claim 10 comprising trimethoprim and a water soluble veterinarily acceptable salt of sulphaquinoxaline.
12. A veterinary composition as claimed in claim 11 wherein the salt of sulphaquinoxaline is obtained by mixing a solution of sulphaquinoxaline with a watersoluble base in a veterinarily acceptable water-miscible solvent. 15. Λ veterinary composition as claimed in claim 12 wherein the water soluble base is an organic base.
13. 14. A veterinary composition as claimed in either claim 12 or claim 13 wherein the base is ethanolamine or diethanolamine.
14. 15. A. veterinary composition as claimed in any one of claims 12 to 14 wherein the water-miscible solvent is polyethylene glycol, propylene glyool, glycerol, glycerol formal or such a solvent mixed with up to 30% v/v of ethanol.
15. 16. A veterinary composition as claimed in any one of claims 10 to 15 comprising from 10 to 50% w/v of a mixture of trimethoprim and sulphaquinoxaline.
16. 17. A veterinary composition as claimed in any one of claims 10 to 15 comprising about 24% w/v of a mixture of trimethoprim and sulphaquinoxaline. -1918. A method for the treatment of protozoal diseases in birds comprising the administration of a veterinary formulation as defined in any one of claims 1 to 17. 5 19. A method as claimed in claim 18 wherein the protozoal disease is coccidiosis.
17. 20. A method for the treatment of bacterial diseases in birds comprising the administration of a veterinary composition as defined in any one of claims 10 1 to 17.
18. 21. A veterinary composition as claimed in claim 1 and substantially as hereinbefore described with reference to the Examples.
19. 22. A method for the treatment of birds as 15 claimed in any one of claims 19 to 21 and substantially as hereinbefore described.
IE730/78A 1977-04-14 1978-04-13 Veterinary compositions IE46866B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB15459/77A GB1596044A (en) 1977-04-14 1977-04-14 Veterinary compositions

Publications (2)

Publication Number Publication Date
IE780730L IE780730L (en) 1978-10-14
IE46866B1 true IE46866B1 (en) 1983-10-19

Family

ID=10059514

Family Applications (1)

Application Number Title Priority Date Filing Date
IE730/78A IE46866B1 (en) 1977-04-14 1978-04-13 Veterinary compositions

Country Status (31)

Country Link
JP (1) JPS53130439A (en)
AR (1) AR216319A1 (en)
AU (1) AU517041B2 (en)
BE (1) BE865964A (en)
CA (1) CA1103162A (en)
CH (1) CH639275A5 (en)
CY (1) CY1260A (en)
DE (1) DE2816064A1 (en)
DK (1) DK162078A (en)
ES (1) ES468750A1 (en)
FI (1) FI781129A (en)
FR (1) FR2387036A1 (en)
GB (1) GB1596044A (en)
GR (1) GR65955B (en)
HK (1) HK85084A (en)
HU (1) HU181027B (en)
IE (1) IE46866B1 (en)
IT (1) IT1102594B (en)
KE (1) KE3418A (en)
LU (1) LU79429A1 (en)
MC (1) MC1187A1 (en)
MY (1) MY8500261A (en)
NL (1) NL7803917A (en)
NO (1) NO781295L (en)
NZ (1) NZ186967A (en)
PH (1) PH16537A (en)
PT (1) PT67903B (en)
SE (1) SE447699B (en)
SG (1) SG53384G (en)
ZA (1) ZA782128B (en)
ZM (1) ZM4078A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3266202D1 (en) * 1981-09-23 1985-10-17 Hoffmann La Roche Manufacturing process of sulfonamide-potentiator solutions and a new sulfanilamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108112A (en) * 1965-03-04 1968-04-03 Wellcome Found Compositions containing sulphaquinoxaline and diaveridine for use in veterinary medicine
BE787236A (en) * 1971-08-05 1973-02-05 Wellcome Found POTENTIALIZATION COMPOSITIONS
GB1469521A (en) * 1973-01-05 1977-04-06 Wellcome Found Antimicrobial preparations

Also Published As

Publication number Publication date
PT67903A (en) 1978-05-01
ZM4078A1 (en) 1979-12-21
PT67903B (en) 1980-04-07
AR216319A1 (en) 1979-12-14
ZA782128B (en) 1979-12-27
ES468750A1 (en) 1979-09-16
PH16537A (en) 1983-11-10
MY8500261A (en) 1985-12-31
GR65955B (en) 1981-01-09
DE2816064A1 (en) 1978-10-19
SE447699B (en) 1986-12-08
SG53384G (en) 1985-03-08
BE865964A (en) 1978-10-13
DK162078A (en) 1978-10-15
CH639275A5 (en) 1983-11-15
IT7848884A0 (en) 1978-04-13
NZ186967A (en) 1981-01-23
JPS53130439A (en) 1978-11-14
CY1260A (en) 1984-11-23
HK85084A (en) 1984-11-09
SE7804176L (en) 1978-10-15
NL7803917A (en) 1978-10-17
KE3418A (en) 1984-08-10
FI781129A (en) 1978-10-15
GB1596044A (en) 1981-08-19
HU181027B (en) 1983-05-30
IE780730L (en) 1978-10-14
JPS6340769B2 (en) 1988-08-12
IT1102594B (en) 1985-10-07
FR2387036B1 (en) 1980-08-29
NO781295L (en) 1978-10-17
FR2387036A1 (en) 1978-11-10
LU79429A1 (en) 1978-11-28
AU3505978A (en) 1979-10-18
MC1187A1 (en) 1978-12-22
AU517041B2 (en) 1981-07-02
CA1103162A (en) 1981-06-16
DE2816064C2 (en) 1988-03-17

Similar Documents

Publication Publication Date Title
US5169846A (en) Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
US9289380B2 (en) Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US6858601B2 (en) Parasiticidal formulation for animals
CA1228547A (en) Solutions of lactic acid salts of piperazinylquinolone-and piperazinyl-azaquinolone- carboxylic acids
IE41828B1 (en) Composition and method for treating scours and/or tetany
US5063219A (en) Anticoccidial composition
US3881003A (en) Compositions containing 3-sulfanilamido-4,5-dimethylisoxazole and a trimethoxybenzyl pyrimidine
JP2778630B2 (en) Compositions for prevention and treatment of coccidiosis
US3065133A (en) Imidazoles for the control of histomoniasis
IE46866B1 (en) Veterinary compositions
US4470978A (en) Synergistic antibacterial composition
GB2386067A (en) Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide &amp; a polymeric species
EP0523523A1 (en) Anticoccidial compositions
US5258373A (en) Anticoccidial compositions
RU2174833C1 (en) Preparation for prophylaxis and treatment of poultry with coccidiosis
EP1129713A1 (en) Veterinary compositions for the treatment of parasitic diseases
US3085937A (en) Method of combating coccidiosis with sulfonamide compositions
GB1574105A (en) Antimalarial compositions containing quinoline methanol derivatives
US2946723A (en) Composition containing para-aminosalicyclic acid and its sodium salt
US3080284A (en) Phenazine for combating lungworm
BR102014031535A2 (en) pharmaceutical formulation and process for obtaining an oral solution containing praziquantel and oral solution containing praziquantel thus obtained
US3305443A (en) Anticoccidial composition and method of using same
JPH01100122A (en) Veterinary synergistic composition, feed premixture and preparation
NL8503099A (en) NUTRIENT AND FEED PRE-MIX WITH INCREASED ANTICOCCIDE EFFECT.
JPS59108718A (en) Animal drug composition

Legal Events

Date Code Title Description
MK9A Patent expired